Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors-Reference-Cited by-同舟云学术

Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors

Published:2006-04 Issue:4 Volume:17 Page:440-447
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Halbert Christine L.¹,Miller A. Dusty¹,Mcnamara Sharon²,Emerson Julia²,Gibson Ronald L.²,Ramsey Bonnie²,Aitken Moira L.³

Affiliation:

1. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.

2. Department of Pediatrics, Cystic Fibrosis Research Center, Children's Hospital and Regional Medical Center, Seattle, WA 98105.

3. Department of Medicine, University of Washington, Seattle, WA 98195.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2006.17.440

Reference32 articles.

1. Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E4orf6

2. EPIDEMIOLOGY OF ADENOVIRUS-ASSOCIATED VIRUS INFECTION IN A NURSERY POPULATION1

3. A SEROEPIDEMIOLOGIC STUDY OF ADENOVIRUS-ASSOCIATED VIRUS INFECTION IN INFANTS AND CHILDREN

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art;Bleeding, Thrombosis and Vascular Biology;2024-09-04

2. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies;Molecular Therapy - Methods & Clinical Development;2024-09

3. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8;Molecular Therapy;2024-08

4. Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors;Scientific Reports;2024-07-10

5. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec;Blood Advances;2024-04-09